Open AccessTEL/AML1 Fusion Gene in Childhood Acute Lymphoblastic Leukemia in Southern Taiwan
Author(s) -
Lin PeiChin,
Chang TaiTsung,
Lin ShiuRu,
Chiou ShyhShin,
Jang RenChin,
Sheen JiunnMing
Publication year - 2008
Publication title -
the kaohsiung journal of medical sciences
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.439
H-Index - 36
eISSN - 2410-8650
pISSN - 1607-551X
DOI - 10.1016/s1607-551x(08)70155-4
Subject(s) - medicine , minimal residual disease , fusion gene , fusion transcript , polymerase chain reaction , leukemia , lymphoblastic leukemia , bone marrow , chromosomal translocation , incidence (geometry) , chromosome , gene , cancer research , oncology , genetics , biology , physics , optics
Chromosomal abnormalities are found in 80–90% of childhood cases of acute lymphoblastic leukemia (ALL). Leukemia‐specific chromosome aberrations not only have prognostic value, but also provide important clues for further investigation into leukogenesis, leukemic cell transformation, and proliferation. This study used reverse transcriptase–polymerase chain reaction techniques to detect transcripts of the leukemia‐specific chromosome fusion gene, TEL/AML1, and to monitor the expression levels of the TEL‐AML1 fusion transcript in ALL patients at sequential intervals during their treatment course. Twenty‐five ALL patients were enrolled, including 20 who were newly diagnosed and five in relapse. The incidence of the TEL/AML1 fusion gene in this study was 32%. The clinical features of our eight TEL/AML1‐positive ALL cases were similar to those in other studies. Blotting analysis of the levels of the TEL‐AML1 fusion transcript was used to detect minimal residual disease. Reduced levels of TEL/AML1 expression were found in four of the six patients whose bone marrow or peripheral blood samples were obtained after treatment. Further investigation with a larger sample size is warranted.